Abstract Retinopathy of prematurity (ROP) is a condition affecting the underdeveloped retinas of premature infants, particularly those exposed to oxygen therapy. While mild cases often resolve on their own, severe ROP can cause retinal detachment, vision loss, or blindness. ROP remains a challenge due to the need to balance treatment benefits and risks. Anti-Vascular Endothelial Growth Factor (VEGF) therapy has emerged as a promising, minimally invasive treatment for significant ROP, offering shorter administration time, ease of use, and reduced need for surgery or anesthesia. This treatment is increasingly initiated in NICUs following routine screening. However, uncertainties remain regarding the best Anti-VEGF drug, dosing strategies, potential systemic side effects, and long-term neurodevelopmental impacts. Under the guidance of an ophthalmologist, Anti-VEGF agents are the preferred first-line therapy in many cases, whereas laser therapy remains the gold standard for others. Neonatologists and paediatricians must be well-versed in ROP screening, risk factors, and treatment approaches to ensure optimal outcomes for preterm infants.
Lodha et al. (Sat,) studied this question.